An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
The clinical development of an inhibitor of cellular proteasome function suggests that compounds targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies. NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome. Substrates of cullin-RING ligases have important roles in cellular processes associated with cancer cell growth and survival pathways. Here we describe MLN4924, a potent and selective inhibitor of NAE. MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumour cells by a new mechanism of action, the deregulation of S-phase DNA synthesis. MLN4924 suppressed the growth of human tumour xenografts in mice at compound exposures that were well tolerated. Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“orthogonally confirmed dose-dependent KAT2A degradation by western blot, and demonstrated that this degradation can be rescued by pre-treatment with a UBA3/NAE1 inhibitor, MLN4924 (37), a proteasome inhibitor, bortezomib (38), and a competing CRBN ligand, pomalidomide (7) (Fig. 1D).”
From Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues (2026) · cites this paper as [37]
In the citing paper
“we cotreated cells with a proteasome inhibitor (bortezomib) or a NEDD8-activating enzyme E1 inhibitor (MLN-4924 32 ) and found that both inhibitors prevented degradation of BTK (Figure 2D).”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [32]
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Self-citationKobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999) · Nature Cell Biology · doi:10.1038/12013 · Cited by 1,543
Modification of Proteins by Ubiquitin and Ubiquitin-Like Proteins
Kerscher, O., Felberbaum, R., & Hochstrasser, M. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010605.093503 · Cited by 1,517
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., & Harper, J. W. (1999) · Genes & Development · doi:10.1101/gad.13.3.270 · Cited by 954
Duda, D. M., Borg, L. A., Scott, D. C., Hunt, H. W., Hammel, M., & Schulman, B. A. (2008) · Cell · doi:10.1016/j.cell.2008.07.022 · Cited by 767
Kamura, T., Sato, S., Iwai, K., Czyzyk-Krzeska, M., Conaway, R. C., & Conaway, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190332597 · Cited by 653
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy
Kane, R. C., Bross, P. F., Farrell, A. T., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-6-508 · Cited by 628
Cited by
Items 801–900 of 1,005
Bayraktar, G., Yuanxiang, P., Confettura, A. D., Gomes, G. M., Raza, S. A., Stork, O., Tajima, S., Suetake, I., Karpova, A., Yildirim, F., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0780-2 · Cited by 31
Johnson, J. R., Crosby, D. C., Hultquist, J. F., Kurland, A. P., Adhikary, P., Li, D., Marlett, J. M., Swann, J., Hüttenhain, R., Verschueren, E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110690 · Cited by 34
Activity-based profiling of cullin–RING E3 networks by conformation-specific probes
Henneberg, L. T., Singh, J., Duda, D. M., Baek, K., Yanishevski, D., Murray, P. J., Mann, M., Sidhu, S. S., & Schulman, B. A. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01392-5 · Cited by 36
Singhal, J., Agrawal, N., Vashishta, M., Priya, N. G., Tiwari, B. K., Singh, Y. P., Rajagopal, R., & Natarajan, K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.300319 · Cited by 31
CAND1-dependent control of cullin 1-RING Ub ligases is essential for adipogenesis
Dubiel, D., Gierisch, M. E., Huang, X., Dubiel, W., & Naumann, M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.01.005 · Cited by 33
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein
Agarwal, A., MacKenzie, R. J., Besson, A., Jeng, S., Carey, A., LaTocha, D. H., Fleischman, A. G., Duquesnes, N., Eide, C. A., Vasudevan, K. B., et al. (2014) · Blood · doi:10.1182/blood-2013-04-497040 · Cited by 33
Maekawa, M., Tanigawa, K., Sakaue, T., Hiyoshi, H., Kubota, E., Joh, T., Watanabe, Y., Taguchi, T., & Higashiyama, S. (2017) · Biology Open · doi:10.1242/bio.029579 · Cited by 39
Lin, S., Shang, Z., Li, S., Gao, P., Zhang, Y., Hou, S., Qin, P., Dong, Z., Hu, T., & Chen, P. (2017) · Oncology Letters · doi:10.3892/ol.2017.7616 · Cited by 32
Lu, P. Z., Guo, Y., Zhu, L., Xia, Y., Zhong, Y., & Wang, Y. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.05.027 · Cited by 31
Luo, Y., Liu, Y., Wu, L., Ma, X., Liu, Q., Huang, F., Zhang, X., Zhang, Y., Zhang, J., Luo, H., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900125 · Cited by 32
Self-citationRational Combinations of Targeted Agents in AML
Bose, P., & Grant, S. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040634 · Cited by 32
Song, T., Liang, S., Liu, J., Zhang, T., Yin, Y., Geng, C., Gao, S., Feng, Y., Xu, H., Guo, D., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007165 · Cited by 31
Tian, D., Wu, Z., Jiang, L., Gao, J., Wu, C., & Hu, H. (2018) · Cancer Science · doi:10.1111/cas.13865 · Cited by 31
AMPK is down‐regulated by the CRL4A‐CRBN axis through the polyubiquitination of AMPKα isoforms
Kwon, E., Li, X., Deng, Y., Chang, H. W., & Kim, D. Y. (2019) · The FASEB Journal · doi:10.1096/fj.201801766rrr · Cited by 31
Naik, S. K., Lam, E. W. ‐., Parija, M., Prakash, S., Jiramongkol, Y., Adhya, A. K., Parida, D. K., & Mishra, S. K. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02838-7 · Cited by 33
Sakai, W., Yuasa‐Sunagawa, M., Kusakabe, M., Kishimoto, A., Matsui, T., Kaneko, Y., Akagi, J., Huyghe, N. D., Ikura, M., Ikura, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76898-2 · Cited by 30
Sanz, D. J., Raivola, J., Karvonen, H., Arjama, M., Barker, H. R., Murumägi, A., & Ungureanu, D. (2021) · Cancers · doi:10.3390/cancers13153727 · Cited by 31
Nightingale, K., Potts, M., Hunter, L., Fielding, C. A., Zerbe, C. M., Fletcher-Etherington, A., Nobre, L., Wang, E. C. Y., Strang, B. L., Houghton, J. W., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108173119 · Cited by 30
Park, K., Qin, L., Kabir, M., Luo, K., Dale, B., Zhong, Y., Kim, A., Wang, G. G., Kanıskan, H. Ü., & Jin, J. J. (2023) · Advanced Science · doi:10.1002/advs.202205573 · Cited by 31
Guihard, S., Ramolu, L., Macabre, C., Wasylyk, B., Noël, G., Abecassis, J., & Jung, A. C. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1584 · Cited by 30
Biophysical Studies on Interactions and Assembly of Full-size E3 Ubiquitin Ligase
Bulatov, E., Martin, E. M., Chatterjee, S., Knebel, A., Shimamura, S., Konijnenberg, A., Johnson, C., Zinn, N., Grandi, P., Sobott, F., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.616664 · Cited by 30
El‐Mesery, M., Seher, A., Stühmer, T., Siegmund, D., & Wajant, H. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12998 · Cited by 30
Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Xolalpa, W., Pérez‐Galán, P., Rodríguez, M. S., & Roué, G. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319220014 · Cited by 31
Zhang, W., Wang, H., Li, Z., Liu, X., Liu, G., Harris, R. S., & Yu, X.-F. (2014) · Journal of Virology · doi:10.1128/jvi.02072-14 · Cited by 30
Hao, R., Song, Y., Li, R., Wu, Y., Yang, X., Li, X., Qian, F., Ye, R. D., & Sun, L. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00349.2018 · Cited by 35
Cellular Cullin RING Ubiquitin Ligases: Druggable Host Dependency Factors of Cytomegaloviruses
Becker, T., Le‐Trilling, V. T. K., & Trilling, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071636 · Cited by 31
Cannito, S., Foglia, B., Villano, G., Turato, C., Delgado, T. C., Morello, E., Pin, F., Novo, E., Napione, L., Quarta, S., et al. (2019) · Cancers · doi:10.3390/cancers11121933 · Cited by 32
The CUL3-SPOP-DAXX axis is a novel regulator of VEGFR2 expression in vascular endothelial cells
Sakaue, T., Sakakibara, I., Uesugi, T., Fujisaki, A., Nakashiro, K., Hamakawa, H., Kubota, E., Joh, T., Imai, Y., Izutani, H., et al. (2017) · Scientific Reports · doi:10.1038/srep42845 · Cited by 31
Gastaldello, S., Callegari, S., Coppotelli, G., Hildebrand, S., Song, M., & Masucci, M. G. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs012 · Cited by 32
Neddylation Facilitates the Antiviral Response in Zebrafish
Yu, G., Liu, X., Tang, J., Xu, C., Ouyang, G., & Xiao, W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01432 · Cited by 30
Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
Nguyen, K. M., & Busino, L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.007 · Cited by 30
NEDD8-conjugating enzyme UBC12 as a novel therapeutic target in esophageal squamous cell carcinoma
Wang, S., Xian, J., Li, L., Jiang, Y., Liu, Y., Cai, L., Hoffman, R. M., Jia, L., Zhao, H., & Zhang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00226-3 · Cited by 29
Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy
Xiang, S., Shi, X., Chen, P., Chen, Y., Bing, S., Jin, X., Cao, J., Wang, J., Yang, B., Shao, X., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105616 · Cited by 30
Neddylation modification of the U3 snoRNA-binding protein RRP9 by Smurf1 promotes tumorigenesis
Du, M., Liu, F., Chang, Y. H., Tong, S., Liu, W., Chen, Y., & Xie, P. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101307 · Cited by 29
Chen, C., Gu, L., Matye, D. J., Clayton, Y., Hasan, M. N., Wang, Y., Friedman, J. E., & Li, T. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111737119 · Cited by 31
Salaroglio, I. C., Belisario, D. C., Bironzo, P., Ananthanarayanan, P., Ricci, L., Digiovanni, S., Fontana, S., Napoli, F., Sandri, A., Facolmatà, C., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02284-7 · Cited by 31
Ramirez, P. W., DePaula-Silva, A. B., Szaniawski, M. A., Barker, E., Bosque, A., & Planelles, V. (2015) · Retrovirology · doi:10.1186/s12977-015-0192-2 · Cited by 29
Wang, X., Li, L., Liang, Y., Li, C., Zhao, H., Ye, D., Sun, M., Jeong, L. S., Feng, Y., Fu, S., et al. (2014) · BioMed Research International · doi:10.1155/2014/974309 · Cited by 29
Neddylation inhibitor MLN4924 suppresses cilia formation by modulating AKT1
Mao, H., Tang, Z., Li, H., Sun, B., Tan, M., Fan, S., Zhu, Y., & Sun, Y. (2019) · Protein & Cell · doi:10.1007/s13238-019-0614-3 · Cited by 29
MLN4924: additional activities beyond neddylation inhibition
Zhou, Q., & Sun, Y. (2019) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1618174 · Cited by 30
Jiang, Y., Liang, Y., Li, L., Zhou, L., Cheng, W., Yang, X., Yang, X., Qi, H., Yu, J., Jeong, L. S., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09472-w · Cited by 30
Self-citationThe application of ubiquitin ligases in the PROTAC drug design
Chen, Y., & Jin, J. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa053 · Cited by 31
Perspectives on the Clinical Development of NRF2-Targeting Drugs
Lastra, D., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_381 · Cited by 31
Cuadrado, A., Cazalla, E., Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, R., Grochot-Przeczek, A., Hayes, J. D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103569 · Cited by 28
Serafini, M. T., Twigger, S. A., Delfas, G., Mallerman, M., Bailey, E. P., Calder, E. D. D., Hammond, E. M., & Conway, S. J. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c10240 · Cited by 28
Ehrentraut, S., Curtis, V. F., Wang, R. X., Saeedi, B. J., Ehrentraut, H., Onyiah, J. C., Kelly, C. J., Campbell, E. L., Glover, L. E., Kominsky, D. J., et al. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-05-0273 · Cited by 28
The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo
Samsa, W. E., Mamidi, M. K., Bashur, L. A., Elliott, R. S., Miron, A., Chen, Y., Lee, B., Greenfield, E. M., Chan, R., Danielpour, D., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1320-6 · Cited by 28
COP9 signalosome is an essential and druggable parasite target that regulates protein degradation
Ghosh, S., Farr, L. A., Singh, A., Leaton, L. A., Padalia, J., Shirley, D.-A. T., Sullivan, D. J., & Moonah, S. N. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008952 · Cited by 31
The E3 ubiquitin ligase Cul4b promotes CD4+ T cell expansion by aiding the repair of damaged DNA
Dar, A. A., Sawada, K., Dybas, J. M., Moser, E. K., Lewis, E. L., Park, E., Fazelinia, H., Spruce, L. A., Ding, H., Seeholzer, S. H., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001041 · Cited by 28
Borgo, C., D’Amore, C., Capurro, V., Tomati, V., Sondo, E., Cresta, F., Castellani, C., Pedemonte, N., & Salvi, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04215-3 · Cited by 28
Pitera, A. P., Szaruga, M., Peak‐Chew, S., Wingett, S., & Bertolotti, A. (2022) · The EMBO Journal · doi:10.15252/embj.2021109985 · Cited by 29
Zhou, Y., Li, M., Shen, T., Yang, T., Shi, G., Wei, Y., Chen, C., Wang, D., Wang, Y., & Zhang, T. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00099 · Cited by 28
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader
Yu, X., Wang, J., Gong, W., Ma, A., Shen, Y., Zhang, C., Liu, X., Cai, L., Liu, J., Wang, G. G., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02618-5 · Cited by 30
Saito, N., Sakakibara, K., Sato, T., Friedman, J., Kufe, D., Vonhoff, D., & Kawabe, T. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0064 · Cited by 25
Stereoselective Synthesis of MLN4924, an Inhibitor of NEDD8-Activating Enzyme
Lee, H. W., Nam, S. K., Choi, W. J., Kim, H. O., & Jeong, L. S. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo2001897 · Cited by 28
Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine
Li, H., Zhou, W., Li, L., Wu, J., Liu, X., Zhao, L., Jia, L., & Sun, Y. (2017) · Neoplasia · doi:10.1016/j.neo.2017.04.003 · Cited by 28
Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth
Ni, S., Chen, X., Yu, Q., Xu, Y., Hu, Z., Zhang, J., Zhang, W., Li, B., Yang, X., Mao, F., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111848 · Cited by 28
Self-citationZhou, L., Zhu, J., Chen, W., Jiang, Y., Hu, T., Wang, Y., Ye, X., Zhan, M., Ji, C., Xu, Z., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03184-4 · Cited by 28
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Bouvier, C., Lawrence, R., Cavallo, F., Xolalpa, W., Jordan, A. M., Hjerpe, R., & Rodríguez, M. S. (2024) · Cells · doi:10.3390/cells13070578 · Cited by 32
Ubiquitination regulates autophagy in cancer: simple modifications, promising targets
Wu, Y., Chen, Y., Tian, X., Shao, G., Lin, Q., & Sun, A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05565-1 · Cited by 29
The role of cullin proteins in gastric cancer
Chen, P., & Yao, G.-D. (2015) · Tumor Biology · doi:10.1007/s13277-015-4154-z · Cited by 27
Malhab, L. J. B., Descamps, S., Delaval, B., & Xirodimas, D. P. (2016) · Scientific Reports · doi:10.1038/srep37775 · Cited by 27
Chen, X., Cui, D., Bi, Y., Shu, J., Xiong, X., & Zhao, Y. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1515550 · Cited by 31
Zou, J., Ma, W., Littlejohn, R., Li, J., Stansfield, B. K., Kim, I., Liu, J., Zhou, J., Weintraub, N. L., & Su, H. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00806.2018 · Cited by 27
Maurya, S., Mary, B., & Jayandharan, G. R. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.164 · Cited by 28
Neddylation regulates excitatory synaptic transmission and plasticity
Brockmann, M. M., Döngi, M., Einsfelder, U., Körber, N., Refojo, D., & Stein, V. (2019) · Scientific Reports · doi:10.1038/s41598-019-54182-2 · Cited by 27
Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor
Wei, L., Wu, Z., Yang, Y., Zhao, M., Ma, X., Li, J.-S., Yang, D., Chen, Z., & Fan, Y. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111858 · Cited by 28
The Role of Cullin-RING Ligases in Striated Muscle Development, Function, and Disease
Blondelle, J., Biju, A., & Lange, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217936 · Cited by 28
Zhang, L., Wang, X., Li, Y., Han, J., Gao, X., Li, S., & Wang, F. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.464 · Cited by 29
Roles of Cullin-RING Ubiquitin Ligases in Cardiovascular Diseases
Diaz, S., Wang, K., Sjögren, B., & Liu, X. (2022) · Biomolecules · doi:10.3390/biom12030416 · Cited by 27
Design and Optimization of Oestrogen Receptor PROTACs Based on 4-Hydroxytamoxifen
Loren, G., Espuny, I., Lope, A. L., Donoghue, C., Verdaguer, X., Gomis, R. R., & Riéra, A. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114770 · Cited by 28
Qi, Y., Rezaeian, A.-H., Wang, J., Huang, D., Chen, H., Inuzuka, H., & Wei, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189140 · Cited by 32
Solid-phase synthesis of tetrasubstituted pyrrolo[2,3-d]pyrimidines
Lee, J. H., & Lim, H. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob06899k · Cited by 27
Le‐Trilling, V. T. K., Wohlgemuth, K., Rückborn, M. U., Jagnjić, A., Maaßen, F., Timmer, L., Katschinski, B., & Trilling, M. (2018) · Journal of Virology · doi:10.1128/jvi.00296-18 · Cited by 27
Eichner, R., Fernández‐Sáiz, V., Targosz, B., & Bassermann, F. C. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.001 · Cited by 32
Clogging the Ubiquitin-Proteasome Machinery with Marine Natural Products: Last Decade Update
Sala, G. D., Agriesti, F., Mazzoccoli, C., Tataranni, T., Costantino, V., & Piccoli, C. (2018) · Marine Drugs · doi:10.3390/md16120467 · Cited by 28
Role of the COP9 Signalosome (CSN) in Cardiovascular Diseases
Milic, J., Tian, Y., & Bernhagen, J. (2019) · Biomolecules · doi:10.3390/biom9060217 · Cited by 29
Muraoka, H., Yoshimura, C., Kawabata, R., Tsuji, S., Hashimoto, A., Ochiiwa, H., Nakagawa, F., Fujioka, Y., Matsuo, K., & Ohkubo, S. (2019) · Cancer Science · doi:10.1111/cas.14209 · Cited by 28
Deng, Q., Zhang, J., Yj, G., She, X., Wang, Y., Wang, Y., & Ge, X. (2017) · PubMed · Cited by 28
Self-citationDevelopment of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold
Xiong, C., Zhou, L., Tan, J., Song, S., Bao, X., Zhang, N., Ding, H., Zhao, J., He, J., Miao, Z., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00242 · Cited by 27
LZTR1: A promising adaptor of the CUL3 family (Review)
Zhang, H., Cao, X., Wang, J., Li, Q., Zhao, Y., & Jin, X. (2021) · Oncology Letters · doi:10.3892/ol.2021.12825 · Cited by 27
Liu, S., Yang, H., Zhao, J., Zhang, Y., Song, A., & Hu, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.484816 · Cited by 31
Ubiquitin at the crossroad of cell death and survival
Chen, Y.-S., & Qiu, X. (2013) · 癌症:英文版 · doi:10.5732/cjc.012.10283 · Cited by 29
Flipping the Switch from G1 to S Phase with E3 Ubiquitin Ligases
Rizzardi, L. F., & Cook, J. G. (2012) · Genes & Cancer · doi:10.1177/1947601912473307 · Cited by 32
The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
Wolenski, F. S., Fisher, C. D., Sano, T., Wyllie, S. D., Cicia, L. A., Gallacher, M., Baker, R. A., Kirby, P. J., & Senn, J. J. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.34 · Cited by 28
VprBP (DCAF1) Regulates RAG1 Expression Independently of Dicer by Mediating RAG1 Degradation
Schabla, N. M., Perry, G. A., Palmer, V., & Swanson, P. C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800054 · Cited by 29
Spironolactone‐induced XPB degradation depends on CDK7 kinase and SCFFBXL18 E3 ligase
Ueda, M., Matsuura, K., Kawai, H., Wakasugi, M., & Matsunaga, T. (2019) · Genes to Cells · doi:10.1111/gtc.12674 · Cited by 30
Shi, C., Kuo, K.-L., Lin, W., Chen, M.-S., Liu, S.-H., Liao, S.-M., Hsu, C.-H., Chang, Y.-W., Chang, H., & Huang, K. (2020) · PubMed · Cited by 26
SUMOylation and NEDDylation in Primary and Metastatic Cancers to Bone
Gomarasca, M., Lombardi, G., & Maroni, P. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.889002 · Cited by 26
Neddylation of HER2 Inhibits its Protein Degradation and promotes Breast Cancer Progression
Xia, X., Hu, T., He, X., Liu, Y., Yu, C., Kong, W., Liao, Y., Tang, D., Liu, J., & Huang, H. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.75852 · Cited by 26
Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?
Lamsoul, I., Uttenweiler‐Joseph, S., Moog‐Lutz, C., & Lutz, P. G. (2015) · Biochimie · doi:10.1016/j.biochi.2015.08.003 · Cited by 26
When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Wu, Z., & Shi, Y. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180010 · Cited by 28
Biochemical and cellular effects of inhibiting Nedd8 conjugation
Leck, Y. C., Choo, Y. Y., Tan, C. Y., Smith, P. G., & Hagen, T. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.06.128 · Cited by 26
Self-citationRicklin, D., & Cines, D. B. (2013) · Blood · doi:10.1182/blood-2013-07-512707 · Cited by 26
Characterization of MRFAP1 Turnover and Interactions Downstream of the NEDD8 Pathway
Larance, M., Kirkwood, K. J., Xirodimas, D. P., Lundberg, E. K., Uhlén, M., & Lamond, A. I. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014407 · Cited by 31
A balance of positive and negative regulators determines the pace of the segmentation clock
Wiedermann, G. E., Bone, R. A., Silva, J. C., Bjorklund, M., Murray, P. J., & Dale, J. K. (2015) · eLife · doi:10.7554/elife.05842 · Cited by 26
Neddylation controls basal MKK7 kinase activity in breast cancer cells
Zhu, T., Wang, J., Pei, Y., Wang, Q., Wu, Y., Qiu, G., Zhang, D., Lv, M., Li, W., & Zhang, J. (2015) · Oncogene · doi:10.1038/onc.2015.323 · Cited by 28
Self-citationCullin 7 mediates proteasomal and lysosomal degradations of rat Eag1 potassium channels
Hsu, P., Ma, Y.-T., Fang, Y.-C., Huang, J.-J., Gan, Y., Chang, P.-T., Jow, G., Tang, C., & Jeng, C. (2017) · Scientific Reports · doi:10.1038/srep40825 · Cited by 29
Cullin E3 Ligase Activity Is Required for Myoblast Differentiation
Blondelle, J., Shapiro, P., Domenighetti, A. A., & Lange, S. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.02.012 · Cited by 27
Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases
Blaquière, N., Villemure, E., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01451 · Cited by 26
Metadata
- Authors
- Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., Cullis, C. A., Doucette, A., Garnsey, J. J., Gaulin, J. L., Gershman, R. E., Lublinsky, A. R., McDonald, A., Mizutani, H., Narayanan, U., Olhava, E. J., Peluso, S., Rezaei, M., Sintchak, M. D., Talreja, T., Thomas, M. P., Traore, T., Vyskocil, S., Weatherhead, G. S., Yu, J., Zhang, J., Dick, L. R., Claiborne, C. F., Rolfe, M., Bolen, J. B., & Langston, S. P.
- Affiliations
- Takeda Oncology (United States) (US)
- Corresponding author
- Soucy, Teresa A.
- ORCID
- Venue
- Nature
- Published
- 2009-04
- Volume
- 458
- Issue
- 7239
- Pages
- 732-736
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2076194625
- Cited by
- 1,990
- References
- 46
- Citations by year
- 2026: 110 · 2025: 120 · 2024: 156 · 2023: 126 · 2022: 137 · 2021: 155 · 2020: 170 · 2019: 149 · 2018: 112 · 2017: 105 · 2016: 108 · 2015: 98 · 2014: 99 · 2013: 100 · 2012: 100
- FWCI
- 32.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- NEDD8-activating enzyme, MLN4924, cullin-RING ubiquitin ligases, ubiquitin-proteasome system, proteasome inhibitors, cancer cell death, tumor xenografts, small molecule inhibitors, antitumour activity
- MeSH terms
- NEDD8 Protein, Animals, Antineoplastic Agents, Cells, Cultured, Cyclopentanes, Enzyme Inhibitors, Female, Humans, Neoplasms, Pyrimidines, Transplantation, Heterologous, Ubiquitins, Ubiquitin-Activating Enzymes, Cullin Proteins, Cell Line, Tumor, Mice, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.